Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Zydus Lifesciences launched PEPAIR™, India's first affordable Oscillating Positive Expiratory Pressure (OPEP) device featuring a 3-resistance system designed to help clear congestion and support effective mucous clearance and improve breathing in patients with COPD, Asthma, and Bronchiectasis.
PEPAIR™ is an innovative, drug-free, handheld device with patented design. More than 90 lakh patients suffer from these chronic respiratory conditions in India. Chronic mucous hypersecretion is a common problem amongst these patients that requires an airway clearance solution for everyday care. PEPAIR™ is being launched in agreement with AeroDel Technology Innovations, an Indian medical device company focused on simplifying inhalation through drug-delivery, pulmonary rehabilitation. In a patient-centric approach, Zydus offers PEPAIR™ at an affordable cost of Rs. 990 per unit.
Speaking on the launch, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, said, “At Zydus, patient-centric innovation is about advancing healthcare in ways that make everyday care more accessible for patients. With PEPAIR™, India's first affordable OPEP device, we are introducing a drug free, handheld solution designed to support better breathing for patients with COPD, asthma and bronchiectasis. We look forward to expanding our efforts in advancing respiratory health through this launch”
The drug-free, handheld device features a patented 3-resistance system to aid mucus clearance and improve breathing in patients with COPD, asthma, and bronchiectasis.
PEPAIR is being launched in partnership with AeroDel Technology Innovations, a domestic medical device firm specializing in inhalation and pulmonary rehabilitation solutions. The device addresses chronic mucous hypersecretion, which affects over 90 lakh patients in India, by promoting airway clearance, reducing cough, and supporting optimal respiratory therapy.
Speaking on the launch, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, said, “PEPAIR™ introduces a patient-centric, drug-free solution to make airway clearance accessible and affordable for millions of patients with chronic respiratory conditions in India.”
Respiratory diseases in India are rising due to air pollution, urbanization, climate-driven allergens, and delayed diagnosis of chronic lung conditions. OPEP therapy, recommended in clinical guidelines, has seen limited adoption due to cost constraints—an access gap PEPAIR™ aims to fill.
Zydus is a leading player in respiratory care in India, with a strong portfolio of oral bronchodilators and inhalation therapies, including Deriphyllin®, Forglyn®, Forglyn® Plus, Odihale®G, and Umiflo® Plus. The company continues to expand its innovation in ICS+LABA, LABA+LAMA, and single-inhaler triple therapies.
Zydus Lifesciences operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
The company’s consolidated net profit rose 7.7% to Rs 1,102.64 crore on 32.3% increase in revenue from operations to Rs 6,780.40 crore in Q3 FY26 over Q3 FY25.
Shares of Zydus Lifesciences shed 0.23% to Rs 907.90 on the BSE.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Ammonium Lactate Cream, 12% (USRLD: Lac-Hydrin Cream®, 12%).
Ammonium lactate cream, 12% is a topical prescription medication indicated for the treatment of dry, scaly skin (xerosis) and an inherited dry skin condition called ichthyosis vulgaris. It is used to moisturise the skin by increasing hydration and, as an alpha-hydroxy acid, helps relieve itching, soften skin, and decrease skin scaling.
Ammonium lactate cream will be manufactured at the group's topical manufacturing site at Changodar, Ahmedabad, and distributed by Viona Pharmaceuticals Inc.
Ammonium lactate cream had annual sales of USD 15 mn in the United States (IQVIA MAT December 2025).
The group now has 430 approvals and has so far filed 505* ANDAs since the commencement of the filing process in FY 2003-04.
Under the terms of the Settlement Agreement:
1. Zydus shall pay Astellas an aggregate amount of USD 120 million.
2. Zydus shall additionally pay a prepaid per unit licensing fee on units of Zydus' generic Mirabegron sold in the US from the date of Settlement Agreement till September 2027.
This Settlement Agreement concludes all litigations between Astellas and the two companies relating to Myrbetriq® and Mirabegron and enables Zydus to continue marketing its generic Mirabegron in the US.
Realty shares tumbled after rallying for four consecutive trading sessions.
At 11:25 IST, the barometer index, the S&P BSE Sensex declined 427.92 points or 0.51% to 83,805.72. The Nifty 50 index fell 121.55 points or 0.47% to 25,832.30.
The broader market underperformed the frontline indices. The BSE 150 MidCap Index dropped 0.71% and the BSE 250 SmallCap Index slipped 0.89%.
The market breadth was negative. On the BSE, 1,557 shares rose and 2,290 shares fell. A total of 234 shares were unchanged.
Direct Tax Collection :
The central government’s net direct tax collections, after accounting for refunds, stood at Rs 19.43 lakh crore so far this fiscal year, up 9.4% from a year earlier. Net corporate tax collection rose 14.51% to Rs 8.90 lakh crore, while taxes from non-corporates, including individuals and Hindu Undivided Families (HUFs), rose 5.91 % to about Rs 10.03 lakh crore.
Buzzing Index:
The Nifty Realty index dropped 1.10% to 28,986.55. The index jumped 4.28% in the past four consecutive trading sessions.
Anant Raj (down 2.26%), Brigade Enterprises (down 1.78%), DLF (down 1.59%), Sobha (down 1.58%) and Godrej Properties (down 1.38%), Prestige Estates Projects (down 1.23%), Oberoi Realty (down 0.83%), Lodha Developers (down 0.78%), SignatureGlobal India (down 0.14%) declined.
Stocks in Spotlight:
Apex Frozen Foods zoomed 15.96% after the company reported a net profit of Rs 10.09 crore in Q3 FY26 as against a net loss of Rs 0.22 crore in Q3 FY25. Net sales for the period under review added up to Rs 264.29 crore, up 14.5% YoY.
Zydus Lifesciences rose 1.61% after the company announced a settlement agreement with Astellas Pharma Inc. in relation to Myrbetriq (generic name: Mirabegron) in the United States.
Mazda zoomed 9.32% after the company’s standalone net profit jumped 17.52% to Rs 8.72 crore in Q3 FY26, compared with Rs 7.42 crore in Q3 FY25. Revenue from operations rose 1.30% to Rs 47.39 crore during the quarter, compared with Rs 46.78 crore in the same quarter last year.
Global markets:
Most Asian market advanced on Thursday, buoyed by Japan’s post-election rally to fresh highs, fueled by renewed confidence in domestic politics and the ruling administration’s economic agenda.
Japanese stocks extending its post-election rally to fresh highs, fueled by renewed confidence in domestic politics and the ruling administration’s economic agenda.
Media reports noted that Takaichi’s snap-election landslide gives her an unusually strong, multi-year mandate to execute policy, which they view as broadly supportive for Japan’s markets and corporate sector.
Overnight in the U.S., the Dow Jones Industrial Average snapped a three-day win streak after a better-than-expected January jobs report.
The blue-chip index lost 66.74 points, or 0.13%, and closed at 50,121.40. The S&P 500 was nearly flat at 6,941.47. The Nasdaq Composite dropped 0.16% to end at 23,066.47.
The Bureau of Labor Statistics’ January nonfarm payrolls report showed job growth of 130,000 in January. Media reports suggested that the job growth gains for January were estimated to be around 55,000. Jobs growth in December was downwardly revised to 48,000.
Strong labor market has reduced the odds for interest rate cuts by the Federal Reserve.
The jobs report follows weaker-than-expected consumer data released on Tuesday. That report showed that consumer spending in December was flat, missing the 0.4% monthly gain expected from economists polled by Dow Jones.
Under the terms of the agreement, Zydus will pay Astellas an aggregate amount of $120 million. In addition, the company will pay a prepaid per-unit licensing fee on sales of its generic Mirabegron in the US from the date of the settlement until September 2027. Other terms of the agreement remain confidential. The settlement enables Zydus to continue marketing its generic Mirabegron product in the US market.
In April 2025, Zydus had informed exchanges that the United States District Court for the District of Delaware had ruled in favour of Astellas on the validity of US Patent No. 10,842,780 related to a sustained-release formulation of mirabegron marketed as Myrbetriq. The court order had upheld the patent’s validity, while issues relating to alleged infringement and damages were scheduled to be litigated at a consolidated jury trial in 2026.
Zydus Lifesciences is a global life sciences company with operations across pharmaceuticals, consumer wellness, and medical technology.
On a consolidated basis, its net profit rose 1.82% to Rs 1042.10 crore while net sales rose 32.34% to Rs 6780.40 crore in Q3 December 2025 over Q3 December 2024.
Orphan drug designation by the USFDA for Desidustat, provides eligibility for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions and a potential seven-year marketing exclusivity upon the USFDA approval.
Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Dapagliflozin Tablets, 5 mg and 10 mg (USRLD: Farxiga® Tablets, 5 mg and 10 mg).
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.
Dapagliflozin tablets will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.
Dapagliflozin tablets had annual sales of USD 10,486.9 mn in the United States (IQVIA MAT December 2025).